Toolkit
Latest project information
HTA - 16/119/02
Pembrolizumab for treating relapsed or refractory, 3rd or 4th line classical hodgkin's lymphoma [ID1062]
Project title: Pembrolizumab for treating relapsed or refractory, 3rd or 4th line classical hodgkin's lymphoma [ID1062]
Call to action: 16/119 16/119 Cancer Filtration Table April 2016
Research type: Evidence Synthesis
Chief investigator: Dr Rob Riemsma
Contractor: Kleijnen Systematic Reviews Ltd
Cost: £83,343.75
Started: September 2017 | Status: Project complete
Links to project documentation
The links and documents below are related to this research and are added as and when they are produced over the life of the project. The information is provided by the researchers and some may have undergone varying editorial, production and publication models, which differ to NIHR Journals Library reports. Links are to both internal (NIHR) and external websites – the NIHR is not responsible for the content of external websites.
Background & Research Questions
Why the research is being done and what is being asked
Methods
How the research is being done
Publications & Outputs
What the research produced
Outcomes & Impact
What happened as a result of the research